Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR
Passive immunotherapy, i.e., treatment with therapeutic antibodies, has been increasingly used over the last decade in several diseases such as cancers or inflammation. However, these proteins have some limitations that single-domain antibodies could potentially solve. One of the main issues of conv...
Saved in:
Main Authors: | Elodie Pothin (Author), Dominique Lesuisse (Author), Pierre Lafaye (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
GlycoVHH: optimal sites for introducing N-glycans on the camelid VHH antibody scaffold and use for macrophage delivery
by: Loes van Schie, et al.
Published: (2023) -
Molecular recognition requires dimerization of a VHH antibody
by: Christopher A. Smith, et al.
Published: (2023) -
Applications and challenges in designing VHH-based bispecific antibodies: leveraging machine learning solutions
by: Michael Mullin, et al.
Published: (2024) -
VHH antibody targeting the chemokine receptor CX3CR1 inhibits progression of atherosclerosis
by: Sarah Low, et al.
Published: (2020) -
Biophysical and biochemical characterization of a VHH-based IgG-like bi- and trispecific antibody platform
by: Lukas Pekar, et al.
Published: (2020)